Sign In
Buy STXS
$1.84
-0.130 (-6.60%)
At Close: Jun 03, 2026
Stereotaxis Reports 2025 Full Year Financial Results
04:01pm, Monday, 09'th Mar 2026
ST. LOUIS, March 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu
Stereotaxis Inc. (NYSEAMERICAN:STXS) Short Interest Update
02:14am, Friday, 06'th Mar 2026
Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report) was the target of a significant increase in short interest in the month of February. As of February 13th, there was short interest totaling 3,271
Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026
09:00am, Thursday, 12'th Feb 2026
ST. LOUIS, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r
Klinikum Fürth Establishes Leading Robotic Heart Arrhythmia Program
08:06am, Monday, 09'th Feb 2026
ST. LOUIS, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the launch of
Stereotaxis Receives FDA Approval for MAGiC Ablation Catheter
08:01am, Tuesday, 06'th Jan 2026
ST. LOUIS, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it obtained U.
3 Underrated Robotics Stocks Poised for Huge Gains
07:03am, Monday, 15'th Dec 2025
The global robotics industry is among the fastest-growing, with projections that it will expand from $50 billion worldwide in 2025 to $111 billion in just five years. Technology develops at a rapid p
Stereotaxis to Participate in Piper Sandler 37th Annual Healthcare Conference
08:58am, Monday, 24'th Nov 2025
ST. LOUIS, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that the compa
STXS Secures FDA Approval for GenesisX to Broaden Surgical Robotics
03:01pm, Thursday, 13'th Nov 2025
Stereotaxis wins FDA clearance for GenesisX, a streamlined robotic system aimed at boosting hospital adoption and accelerating growth.
Stereotaxis, Inc. (STXS) Q3 2025 Earnings Call Transcript
07:51pm, Tuesday, 11'th Nov 2025
Stereotaxis, Inc. ( STXS ) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants David Fischel - CEO & Chairman Kimberly Peery - Chief Financial Officer Conference Call Participants
Stereotaxis Inc. (STXS) Reports Q3 Loss, Misses Revenue Estimates
06:11pm, Tuesday, 11'th Nov 2025
Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
Stereotaxis Reports 2025 Third Quarter Financial Results
04:01pm, Tuesday, 11'th Nov 2025
ST. LOUIS, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul
GenesisX Robotic Magnetic Navigation System Receives U.S. FDA Clearance
04:05pm, Monday, 10'th Nov 2025
ST. LOUIS, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv
Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025
09:00am, Tuesday, 21'st Oct 2025
ST. LOUIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r
Stereotaxis (NYSEAMERICAN:STXS) Stock Price Up 3.7% – What’s Next?
02:38am, Tuesday, 21'st Oct 2025
Stereotaxis Inc. (NYSEAMERICAN:STXS - Get Free Report)'s share price was up 3.7% during trading on Monday. The stock traded as high as $3.13 and last traded at $3.10. Approximately 338,622 shares were
Stereotaxis Rolls Out Synchrony System in EU and Files for FDA Approval
10:21am, Monday, 20'th Oct 2025
STXS expands its digital surgery vision with the EU launch of its Synchrony System and an FDA submission for market entry.
